Long survival of PD-L1-positive mediastinal sarcomatoid carcinoma after immunotherapy and anti-angiogenic target therapy: A case report
Shuling Wu, Danping Wang, Qiong Fu, Yingying Ding · 2026
Read Long survival of PD-L1-positive mediastinal sarcomatoid carcinoma after immunotherapy and anti-angiogenic target therapy: A case report by Shuling Wu, Danping Wang, Qiong Fu, Yingying Ding (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13280351.txt.
Description
Shuling Wu and colleagues report a 2026 case of long survival in a rare chest cancer after immune and vessel therapy. Mediastinal sarcomatoid carcinoma arises in the chest centre and often ends poorly. No past work tested immunotherapy plus anti angiogenic therapy, which starves tumour vessels, for it. Their patient was a seventy four year old woman. Tumour tests showed high PD-L1 expression, an immune brake protein, with a score of eighty.
She first got two cycles of chemotherapy and one cycle of radiotherapy with anlotinib, a vessel blocker, for stable disease. Two cycles of durvalumab immunotherapy with anlotinib then gave a partial response. Immunotherapy stopped due to severe side effects, while anlotinib went on. She stays alive with no disease progression past forty two months. The pair of therapies may suit PD-L1 high cases of this rare cancer.
Catalog record
| CREATOR | Shuling Wu, Danping Wang, Qiong Fu, Yingying Ding |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34819 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |